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Methamphetamine use among men who have sex with men (MSM) is associated with increased HIV prevalence, due to
increased engagement in high-risk sexual behavior. Fifty-three HIV-negative, methamphetamine-using MSM were enrolled in
a biobehavioral combination prevention intervention in Los Angeles, CA, to assess the feasibility of administering postexposure
prophylaxis (PEP) in combination with contingencymanagement (CM) to prevent HIV seroconversion.The study combined a CM
behavioral intervention targeting reductions in methamphetamine use with a PEP biomedical intervention for HIV prevention.
Those who reported recent exposure to HIV were initiated on tenofovir/emtricitabine- (Truvada-) based PEP (𝑛 = 35). This
secondary analysis sought to determine whether sexual risk taking was associated with PEP adherence. Regression analyses
controlling for participant sociodemographics demonstrated that, at baseline, increased number of lifetime sexually transmitted
diseases (STDs; Coef. = −0.07; 95% CI= (−0.12) – (−0.01)) and recent episodes of unprotected anal intercourse (UAI; Coef. = −0.01;
95% CI= (−.01) – (−0.002)) were associated with reductions in medication adherence. Given these associations between baseline
sexual risk and PEP adherence, providers working with high-riskMSMmay look to target reductions in sexual risk taking; this will
reduce direct risk of HIV infection and may work to optimize medication adherence in the case of PEP initiation.
1. Introduction
In the United States, men who have sex with men (MSM)
exhibit disproportionately high incidence and prevalence of
HIV infection. MSM represent an estimated 4.7–9.2% of the
total United States (US) population [1] yet, in 2009, accounted
for 61% of all new HIV infections in the US [2]. Risk
factors for HIV infection have been widely documented and
amongMSM in the US include unprotected anal intercourse,
high number of male partners [3], and methamphetamine
use [4, 5]. Postexposure prophylaxis (PEP) is a biomedical
intervention intended to reduce the likelihood of HIV sero-
conversion after exposure to the virus. Combination preven-
tion approaches combine biomedical interventions like PEP
with behavioral (e.g., cognitive behavioral therapy, motiva-
tional interviewing) and/or structural (e.g., needle exchange,
condom distribution) interventions, thereby optimizing the
likelihood of proper adherence to the PEP medication while
also reducing the risk factors placing participants at risk for
HIV seroconversion.
1.1. Combination Prevention Interventions. Combination pre-
vention interventions integrate behavioral, biomedical, and/
or structural intervention strategies in the attempt to max-
imize the likelihood of intervention success and opti-
mize intervention outcomes [6]. The increasing applica-
tion of combination prevention interventions in the US
represents the impact of the National HIV/AIDS Strategy
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Figure 1: Proposed causation model.
(NHAS) [7], which highlighted the importance of combi-
nation approaches in successfully reducing HIV transmis-
sion. Recent disease epidemic models have demonstrated
that movement away from purely behavioral interventions
towards combination efforts may reduce the long-term costs
of care as well as the overall number of persons living with
HIV in the US [8, 9]. In addition, such efforts may be most
cost effective when targeted for communities or populations
at highest risk for HIV transmission.
1.2. Methamphetamine Use and HIV Sexual Risk among
MSM. Methamphetamine is the most frequently used sub-
stance among MSM, following alcohol and marijuana,
particularly in urban centers along the western US [10].
Among MSM, methamphetamine use has been associated
with increased high-risk sexual behaviors [11–14]. Results
have shown an ecological association between intensity of
methamphetamine use and HIV infection; as the intensity of
methamphetamine use increases, so does the likelihood of an
observed HIV-positive status [5].
1.3. Postexposure Prophylaxis. Postexposure prophylaxis is
the preventative strategy of taking 28 days of antiretroviral
therapy (ART), initiated rapidly after an exposure to HIV,
to reduce the odds of HIV acquisition [15]. Though there is
currently limited clinical data for nonoccupational use [16],
PEP is currently recommended for use after high-risk sexual
exposures and/or needle sharing [15]. Failure to properly
adhere to a prescribed PEP treatment regimen may not only
fail to deter HIV seroconversion, but may also result in viral
resistance which would make subsequent treatment of the
disease with ARTmore difficult [16]. As such, difficult to treat
populations (e.g., substance users, the homeless) may require
additional intervention support in order to ensure proper
adherence to a prescribed PEP regimen.
1.4.The Efficacy and Feasibility of PEP for High-RiskMSM. In
a randomized noninferiority trial conducted in San Francisco
[17], PEP-related adherence outcomes were contrasted across
groups of low- and high-sexual risk-taking MSM. Though
noninferiority was corroborated in the group of low risk-
taking MSM, the high-risk MSM required more counseling
support to achieve comparable results. Those that did not
receive enhanced counseling displayedmarginally lower rates
of PEP course completion; evidence from animal models
suggests that truncated courses of PEP severely compromise
the efficacy of the intervention [18].
Sexual risk-takingMSMprescribed PEPmay thus require
additional motivation and support, such as that provided
by combination prevention methods, to optimize levels of
medication adherence and to maximize likelihood of course
completion. Preliminary pilot data from a behavioral/bio-
medical combination prevention intervention in Los Angeles
demonstrated that high-risk, methamphetamine-usingMSM
receiving PEP and undergoing a contingency management
intervention to reduce methamphetamine use produced lev-
els of medication adherence and rates of course completion
comparable to historical cohorts [19–21]. The behavioral
component of the intervention (i.e., contingency manage-
ment to reduce methamphetamine use) was associated with
reductions in participant methamphetamine use; it was also
demonstrated that years of heavy methamphetamine use
at baseline, and ongoing methamphetamine use during the
course of the studywere both associatedwith suboptimal PEP
medication adherence and/or course completion.
MSM with multiple risk factors for HIV infection, such
as high-risk sexual behaviors and methamphetamine use,
may represent a prime target population for combination
prevention interventions designed to simultaneously reduce
HIV risk behavior and incident HIV infection. A causation
model illustrating the proposed linkages between metham-
phetamine use, high-risk sexual behaviors, the PEP/CM
combination prevention intervention, and likelihood of HIV
seroconversion is provided in Figure 1. This secondary
analysis sought to determine if lifetime and/or recent levels
of high-risk sexual behavior were associated with poorer
medication adherence and/or course completion among a
sample of high-risk HIV negative, methamphetamine-using
MSM. It was hypothesized that both recent and lifetime
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sexual risk taking would be associated with reductions in
PEP medication adherence and odds of course completion.
This hypothesized association would corroborate the dashed
arrow in Figure 1.
2. Materials and Methods
The Institutional Review Boards for UCLA and Friends
Research Institute provided oversight for all study activities
and approved all study-related documents, materials, and
procedures. Exact procedures of the contingency manage-
ment behavioral intervention (including payout schedules)
are published elsewhere [21].
2.1. Participants. Participants were recruited between March
2009 and August 2010 using targeted ads posted in local gay
magazines and the distribution of flyers and club cards in the
settings where methamphetamine-using MSM congregate
(e.g., dance clubs, bathhouses, coffee houses, and gyms).
Potential participants were eligible if they self-identified as
MSM, were at least 18 years of age, HIV uninfected on rapid
HIV ELISA testing, self-reported methamphetamine use
within the previous 30 days, and reported unprotected anal
intercourse (UAI) with an HIV-positive or HIV-serostatus-
unknown partner in the previous 90 days.
2.2. Study Procedures. All study procedures were conducted
at a community research site in LosAngeles, CA.At a baseline
visit, all eligible participants underwent informed consent,
completed baseline assessments, received rapid HIV testing
(OraQuick Advance, OraSure technologies, Bethlehem, PA),
provided specimens for syphilis, Neisseria gonorrhoeae, and
Chlamydia testing, and received a medical examination.
Those who reported a high-risk sexual or drug exposure
episode with an HIV-positive or serostatus-unknown source
within the preceding 72 hours immediately initiated teno-
fovir isoproxil fumarate + emtricitabine (Truvada, Gilead
Sciences), one tablet daily, for 28 days. All other participants
received a 4-day “starter pack” of Truvada to be initiated only
in the future case of a high-risk exposure to HIV. Thirty-five
participants initiated PEP during the study period and com-
prise the analytic sample. One incident of HIV seroconver-
sion was observed in a participant who reported medication
nonadherence and multiple subsequent sexual exposures.
Further study procedures and information on the incident
seroconversion are described in detail elsewhere [21].
2.3. Assessments. Baseline assessments included demograph-
ics, methamphetamine use (DSM-IV-TR), sexual risk behav-
iors (Behavioral Questionnaire-Amphetamine [BQA-II]),
medication adherence, HIV serostatus, and sexually trans-
mitted diseases (STDs, urine sample, self-performed rectal
swab for nucleic acid amplification [NAAT] for N. gon-
orrhoeae and C. trachomatis and pharyngeal swab for N.
gonorrhoeae, and syphilis testing via serum rapid plasma
reagin [RPR] assay). HIV and STD testing were performed
at three-month followup; HIV RNA testing was performed
only in the event of suspicion of acute HIV seroconversion.
Further specifics regarding biologic testing and monitoring
are provided elsewhere [21].
To determine medication adherence, participants were
asked to report if they had missed any doses of the Truvada
medication each time they came on site for a scheduled
study appointment or to pick up additional medication.
Proportional PEP adherence is defined as the number of
doses taken divided by the total number of doses prescribed
(e.g., X/28). If a participant missed more than 3 consecutive
doses at any point during the 28-day regimen, they were
discontinued from the medication and were considered to
have not achieved course completion. Thus, course com-
pletion was a dichotomous (0/1) variable that indicates that
a participant never missed more than three consecutive
doses and was thus able to continue taking the prescribed
medication through to the last dose.
There were two measures of high-risk sexual behaviors
in this study. Recent high-risk sexual behavior was opera-
tionalized as the self-reported number of episodes of UAI
during past six months at baseline. Lifetime high-risk sexual
behavior was operationalized as the self-reported number of
STDs acquired over the life course at baseline.
2.4. Statistical Analysis. For descriptive analyses, counts and
percentages were provided for nominal variables, while
means and standard deviations were provided for continu-
ous or count variables. Multivariate analyses included both
ordinary least squares (OLS) regressions (for analyses of pro-
portional medication adherence) and logistic regressions (for
analyses of course completion; 0 = did not complete course,
1 = completed course). All multivariate analyses included
participants’ race/ethnicity and sexual identity as statistical
controls. In no case were participants’ race/ethnicity or sexual
identity significantly associated with PEP-related outcomes,
and thus their coefficient estimates were omitted. Three
participants were unwilling to disclose sexual risk behaviors
at baseline. Due to the small sample sizes, results are reported
as significant beginning at 𝑃 ≤ 0.1. All analyses were carried
out using Stata version 10SE (StataCorp, College Station, TX).
3. Results
Participant sociodemographics are presented in Table 1.
Most participants (60%) identified as white, with most
nonwhite participants identifying as Hispanic/Latino (𝑛 = 9;
25.7%). Most participants identified as gay (85.7%), and most
reported having a high school diploma or GED equivalent
(60.0%). Self-reported annual income in the sample was
low, with nearly half (48.6%) of the sample reporting yearly
earnings of less than or equal to $15,000, and nearly three-
quarters of the sample (74.3%) reporting earning less than or
equal to $30,000 a year. Most participants reported renting or
owning a house/apartment (54.3%), though a sizable minor-
ity reported being homeless (11.4%). Self-reported lifetime
history of STDs was common (𝑀STD = 1.8; SD = 2.2), as were
counts of recent episodes of UAI (𝑀UAI = 11.9; SD = 26.5).
Table 2 presents overall proportional PEP adherence
rates; nearly half (48.6%) of all participants who initiated
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Table 1: PEP-initiator sociodemographic characteristics (𝑁 = 35).
Characteristic 𝑁 (%) or mean (SD)
Age 34.1 (7.4)
Race/ethnicity
Caucasian/white 21 (60.0%)
Non-White 14 (40%)
Sexual identity
Gay 30 (85.7%)
Non-gay 5 (14.3%)
Educational attainment
Less than HS 1 (2.9%)
HS Diploma/GED 21 (60.0%)
BA/BS 9 (25.7%)
Post graduate 4 (11.4%)
Annual income
≤$15,000 17 (48.6%)
$15,001–$30,000 9 (25.7%)
$30,001–$60,000 6 (17.1%)
>$60,000 3 (8.6%)
Housing status
Own/Rent House/Apt. 19 (54.3%)
Group Housing/Sober Living 3 (8.6%)
With Family/Friends 9 (25.7%)
Homeless 4 (11.4%)
Sexually transmitted diseases
Lifetime 1.8 (2.2)
# Times unprotected anal intercoursea
Past 6 months 11.9 (26.5)
a
𝑛 = 32.
Table 2: Adherence to post-exposure prophylaxis medication regi-
men.
Proportional adherence Freq. Percent Cumulative
0.04 3 8.6 8.6
0.07 2 5.7 14.3
0.14 1 2.9 17.1
0.25 1 2.9 20.0
0.46 1 2.9 22.9
0.57 2 5.7 28.6
0.77 1 2.9 31.4
0.82 1 2.9 34.3
0.89 1 2.9 37.1
0.93 1 2.9 40.0
0.96 4 11.4 51.4
1.00 17 48.6 100.0
Total 35 100
PEP took all 28 doses of the Truvada medication. Another
five (14.3%) participants were at least 90% adherent to the
medication regimen, meaning 62.9% of the PEP-initiators
were ≥90% adherent. Eight PEP-initiators (22.9%) failed to
complete half of the 28-day treatment regimen. Of the 35 PEP
initiators, 25 (71.4%) continued taking the medication with
sufficient frequency to avoid discontinuation and completed
the prescribed course (i.e., course completion).
Table 3 provides the results of six separate multivariate
regressions, threemodels for each of the two PEP-related out-
comes (medication adherence, course completion). Results
included under Model 1 provide associations between par-
ticipants’ lifetime number of STDs and medication adher-
ence/course completion. When controlling for covariates,
participants’ lifetime number of STDs was significantly asso-
ciated with both PEP adherence and course completion.
For each additional STD reported at baseline, participants’
estimated proportional medication adherence reduced by
0.07 (approximately 2 of the 28 total doses), and their odds
of course completion reduced by an estimated 31%.
Results appearing under Model 2 provide associations
between recent episodes of UAI and medication adherence/
course completion. Participants’ self-reported count of recent
UAI was significantly associated with both participants’
PEP adherence and odds of course completion. For each
additional episode ofUAI in the past sixmonths, participants’
estimated proportional medication adherence reduced by
0.01 and their odds of completing the PEP course reduced by
an estimated 6%. Analyses appearing under Model 3 regress
PEP outcomes on STDs and episodes of UAI simultaneously.
Results revealed that only the number of recent episodes
of UAI remains significantly associated with PEP outcomes
when all cofactors are included simultaneously. However, an
examination of the coefficients of determination (i.e., 𝑅2,
Pseudo-𝑅2) revealed a nontrivial increase in the amount
of variance explained in each model when including both
factors simultaneously. This indicates that the significance
test on the coefficient for STDs is likely being influenced by
the small sample size (𝑛 = 32) and relatively large number of
factors (𝑘 = 4) included in the model and may represent a
type II hypothesis testing error rather than a genuine lack of
statistical association. Additional factors tested for inclusion
in the analysis included self-reported methamphetamine use
(or methamphetamine and an other substance use) during
sex, current relationship status, and total number of recent
nonprimary sexual partners. In no case were these factors
significantly associated with PEP adherence, and were thus
omitted from the final models.
4. Discussion
Given the associations between methamphetamine use,
high-risk sexual behaviors, and HIV infection/transmission
among MSM, there is a need to develop effective interven-
tions to prevent the acquisition and transmission of HIV
among this extremely high-risk population [14]. At baseline,
participants reported an average of almost two prior STDs
and 12 recent episodes of UAI in the past six months.
This was commensurate with the eligibility criteria of the
study, one of which was self-report UAI (either receptive
or insertive) with an HIV-positive or serostatus-unknown
partner in the past threemonths. Given the well-documented
association between methamphetamine use and high-risk
sexual behaviors among MSM, as well as the urgency to
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Table 3: Multivariate analyses of PEP adherence and course completion.
Outcome variable Factor(s) Model 1 (𝑁 = 35) Model 2 (𝑛 = 32) Model 3 (𝑛 = 32)
Coef. 95% CI Coef. 95% CI Coef. 95% CI
PEP adherence
STDs −0.07∗ (−0.12)–(−0.01) — — −0.04 (−0.10)–0.03
UAI — — −0.01∗∗ (−0.01)–(−0.002) −0.01∗∗ (−0.01)–(−0.002)
𝑅
2
= 0.17 𝑅
2
= 0.28 𝑅
2
= 0.32
AOR 95% CI AOR 95% CI AOR 95% CI
Course completion
STDs 0.69† 0.46–1.01 — — 0.71 0.42–1.21
UAI — — 0.94∘ 0.87–1.01 0.94∘ 0.87–1.01
Pseudo 𝑅2 = 0.12 Pseudo 𝑅2 = 0.22 Pseudo 𝑅2 = 0.27
∘
𝑃 ≤ 0.1; †𝑃 = 0.058; ∗𝑃 ≤ 0.05; ∗∗𝑃 ≤ 0.01.
Controls: Race/Ethnicity, Sexual Identity.
STDs: Sexually Transmitted Diseases (Lifetime).
UAI: Unprotected Anal Intercourse (past 6 months).
target sexual risk behaviors among MSM in HIV prevention
efforts, it is important to determine whether sexual risk
taking impacted medication adherence rates and/or the
likelihood of course completion among this sample of high-
risk, methamphetamine-using MSM.
Findings demonstrated that medication adherence was
comparable with other, nonsubstance using populations [19,
20, 22], with 63% of all participants who initiated PEP achiev-
ing a minimum of 90% adherence to the 28-day medication
regimen. When controlling for participant race/ethnicity
and sexual identity, separate analytical models revealed that
increased numbers of lifetime STDs and recent episodes of
UAI were both associated with reductions in PEPmedication
adherence and course completion. When both factors (and
the aforementioned controls) were estimated simultaneously,
only recent episodes of UAI remained significantly associated
with the PEP-related outcomes, though the likelihood of a
type II hypothesis testing error for the coefficient on STDs is
high.When all factors were included simultaneously, analytic
models succeeded at explaining a third of all variance in
medication adherence and a quarter of all variation in course
completion.
Individuals undertaking high levels of sexual risk are
prime candidates for efficacious HIV prevention strategies,
including administration of biomedical interventions such as
PEP. However, insofar as these same individuals are empiri-
cally less likely to properly adhere to such interventions, there
is potential for the development of drug-resistant strains of
HIV or other risks associated with suboptimal medication
adherence. As such, the acceptability of PEP among popula-
tions unlikely to adhere to prescribed regimensmay be drawn
sharply into question. Any evidence revealing associations
between past behavior and estimated PEP-adherence must,
then, be closely attended.
The intention of combination prevention interventions is
to provide, through the integration of multimodal interven-
tion techniques, additional support and motivation to those
at highest risk for intervention noncompliance to complete
their assigned medication regimen and maximize the likeli-
hood of HIV nonseroconversion. The PEP/CM combination
prevention intervention described here was designed in part
to reduce methamphetamine use among participants; prior
results indicated that the intervention was associated with
reductions in methamphetamine use and high-risk sexual
behavior [21]. Reduction of high-risk sexual behaviors was
not a direct targeted outcome of the CM behavioral inter-
vention, though previous research has also demonstrated
that reductions in methamphetamine use among MSM were
accompanied by reductions in high-risk sexual behaviors
[23]. Given the results presented here, combination preven-
tion interventions that provide PEP to high-riskMSM should
consider the inclusion of behavioral interventions explicitly
designed to reduce substance use and concomitant high-
risk sexual behaviors. In this way, sexual risk taking may be
preemptively targeted for reduction, increasing the likelihood
that a PEP regimen will be adhered to and/or completed.
Such reductions in high-risk sexual behaviors would
benefit high-risk MSM in multiple ways, including reducing
the need for PEP, lowering risk of infection with HIV and
STDs, and maximizing adherence and likelihood of course
completion if PEP is initiated. The direct reductions in
the need for PEP initiation as well as decreased risk for
infection with HIV or other STDs are of primary interest.
However, for those who reduce but do not eliminate high-
risk behaviors and still require PEP initiation, results pre-
sented here also indicate that PEP-related outcomes may be
maximized, further decreasing the likelihood of HIV sero-
conversion. Perhaps most promisingly, given the intersecting
and reinforcing nature of methamphetamine use and high-
risk sexual behaviors among MSM, combination prevention
interventions designed to reduce both while simultaneously
providing biomedical interventions to avoid seroconversion
would provide a more holistic, syndemic approach to HIV-
prevention among high-risk MSM.
This study was limited by the face-to-face, self-reported
nature of the sexual risk data collected at baseline. Fur-
thermore, given the highly specialized nature of the sample
(methamphetamine-usingMSM living in LosAngeles county
engaged in at least one high-risk sexual behavior in the
past three months), results presented here may not be
generalizable to other populations. Lastly, the small sample
size and use of multivariate inferential statistics necessitated
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the use of relaxed statistical reporting standards, increasing
the risk of both type I and type II hypothesis testing errors.
However, in spite of these limitations, the results presented
here provide evidence that both recent and lifetime high-
risk sexual behaviors are associated with PEP-related out-
comes. Given that high-risk, methamphetamine-using MSM
are often targeted for HIV-prevention interventions, includ-
ing PEP combination prevention interventions, the results
presented here provide important evidence to researchers
looking to develop combination prevention interventions to
this and similar high-risk populations.
High-risk sexual behavior is a serious public health con-
cern among MSM communities across the US. As indicated
by the recently implemented NHAS, combination prevention
interventions are being tested for their efficacy in augmenting
purely biomedical means of preventing HIV transmission in
this and other populations disproportionately affected by the
HIV epidemic. The ability to effectively determine factors
endemic to such high-risk populations that may prevent
proper implementation and adherence to prescribed biomed-
ical interventions is crucial to this effort.The results presented
here indicate that self-reported sexual risk taking is associated
with reduced rates of medication adherence and likelihood
of course completion amongmethamphetamine-usingMSM.
Thus, future combination prevention interventions target-
ing high-risk MSM should include behavioral intervention
components specifically designed to reduce high-risk sexual
behaviors that can, thereby, serve to optimize biobehavioral
outcomes.
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